{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:30Z","timestamp":1794047430718,"version":"4.8.0"},"reference-count":12,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2023.282731","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T04:05:25Z","timestamp":1680753925000},"page":"1984-1985","source":"Crossref","is-referenced-by-count":1,"title":["Can we cure relapsed\/refractory Hodgkin lymphoma without a stem cell transplant?"],"prefix":"10.3324","volume":"108","author":[{"given":"Matthew G.","family":"Mei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"49885","doi-asserted-by":"crossref","unstructured":"Ding K, Liu H, Ma J. Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial. Haematologica. 2023; 108(8):2146-2154.","DOI":"10.3324\/haematol.2022.282266"},{"key":"49886","doi-asserted-by":"crossref","unstructured":"Moskowitz AJ, Shah G, Sch\u00f6der H. Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol. 2021; 39(28):3109-3117.","DOI":"10.1200\/JCO.21.01056"},{"key":"49887","doi-asserted-by":"crossref","unstructured":"Mei MG, Lee HJ, Palmer JM. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022; 139(25):3605-3616.","DOI":"10.1182\/blood.2022015423"},{"key":"49888","doi-asserted-by":"crossref","unstructured":"Song Y, Gao Q, Zhang H. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia. 2020; 34(2):533-542.","DOI":"10.1038\/s41375-019-0545-2"},{"key":"49889","doi-asserted-by":"crossref","unstructured":"Younes A, Santoro A, Shipp M. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016; 17(9):1283-1294.","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"49890","doi-asserted-by":"crossref","unstructured":"Armand P, Shipp MA, Ribrag V. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016; 34(31):3733-3739.","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"49891","doi-asserted-by":"crossref","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015; 28(6):690-714.","DOI":"10.1016\/j.ccell.2015.10.012"},{"key":"49892","doi-asserted-by":"crossref","unstructured":"Chen R, Zinzani PL, Lee HJ. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019; 134(14):1144-1153.","DOI":"10.1182\/blood.2019000324"},{"key":"49893","doi-asserted-by":"crossref","unstructured":"Armand P, Kuruvilla J, Michot J-M. KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure. Blood Adv. 2020; 4(12):2617-2622.","DOI":"10.1182\/bloodadvances.2019001367"},{"key":"49894","doi-asserted-by":"crossref","unstructured":"Armand P, Engert A, Younes A. Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018; 36(14):1428-1439.","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"49895","doi-asserted-by":"crossref","unstructured":"Yhim H-Y, Eshet Y, Metser U. Risk stratification for relapsed\/refractory classical Hodgkin lymphoma integrating pretransplant Deauville score and residual metabolic tumor volume. Am J Hematol. 2022; 97(5):583-591.","DOI":"10.1002\/ajh.26500"},{"key":"49896","doi-asserted-by":"crossref","unstructured":"Kurtz DM, Soo J, Co Ting Keh L. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 2021; 39(12):1537-1547.","DOI":"10.1038\/s41587-021-00981-w"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282731\/75519","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282731\/75860","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11048\/75519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:51Z","timestamp":1794045831000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.282731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":12,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.282731","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,6]]}}}